AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 42 min read$HALO

Torley Helen sold $107K of HALO

Torley Helen (PRESIDENT AND CEO) sold 1,610 shares of HALOZYME THERAPEUTICS, INC. (HALO) at $66.39 ($0.11M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Torley Helen
Published Jun 4, 2026, 12:06 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$HALO
Neutral
medium confidence
Mentioned
$HALO
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HALONeutralLow
01

Why it matters

This is a disclosure of an officer/director open-market sale; absent additional company-specific catalysts, it mainly informs sentiment and positioning rather than fundamentals.

02

Market read

Traders may monitor for follow-on insider activity, but the 10b5-1 framing suggests limited incremental information.

03

What to watch

The article provides no context on whether this sale is part of a larger scheduled program, nor any subsequent insider buys/sales around the same window.

Relevance 6/10Novelty 3/10Timing: Filed June 3; sale occurred June 1 (10b5-1 open-market).

Background

The article is an SEC Form 4 insider transaction disclosure for Halozyme Therapeutics, Inc. (HALO).

Company-level read

Ticker impact

$HALONeutralMedium confidence
Context

SEC Form 4 shows HALO’s President/CEO Torley Helen sold 1,610 shares in an open-market transaction under a 10b5-1 plan.

Expected impact

Limited near-term impact; any reaction is likely sentiment-driven rather than catalyst-driven.

Evidence & confidence

The filing is a routine insider transaction with explicit 10b5-1 pre-arrangement, reducing inference of new negative information.

Market effects

Sector

Minimal; single-company insider transaction without new clinical/regulatory or financial datapoints.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

10b5-1 sales can still coincide with periods of heightened risk; traders may treat repeated insider selling as a weak sentiment signal.

Key entities

  • issuer
    HALO

    Halozyme Therapeutics, Inc.; subject of the insider transaction disclosure.

  • insider
    Torley Helen

    President and CEO who sold shares under a pre-arranged Rule 10b5-1 plan.

Read at source← All news

Related articles

AUG 7
$NTRAMedAI 8/10

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Natera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.

newsable.asianetnews.com6 min
AUG 7
$HALOHighAI 9/10

Halozyme climbs after record Q2 results and higher 2026 outlook

Halozyme Therapeutics (HALO) shares rose about 15% after the company reported record Q2 2026 results and raised 2026 guidance, according to Halozyme’s investor release. Q2 total revenue increased 48% to $481 million, royalty revenue rose 50% to $307.7 million. Full-year 2026 revenue guidance was raised to $1.835B-$1.910B and non-GAAP diluted EPS to $8.65-$9.00.

quiverquant.com4 min
AUG 7
$HALOHighAI 9/10

Why is Halozyme Therapeutics stock surging today?

Halozyme Therapeutics shares rose about 6.1% pre-open after the company reported record Q2 2026 results. Total revenue increased 48% to $481 million and non-GAAP EPS was $2.28, both above expectations. Royalty revenue hit $307.7 million. Halozyme raised full-year 2026 guidance to non-GAAP EPS of $8.65-$9.00 and revenue of $1.835-$1.910 billion, and said it signed five new ENHANZE/Hypercon deals year-to-date.

investing.com2 min
AUG 7
$HALOMedAI 8/10

Halozyme Therapeutics Q2 Earnings Call Highlights

Halozyme Therapeutics (NASDAQ:HALO) reported Q2 royalty momentum for VYVGART Hytrulo, with royalty revenue up 143% to $72.6M and total VYVGART brand sales up 60% to $1.5B. Other royalty revenue rose 85% to $54.4M. Halozyme raised 2026 guidance to $1.835B-$1.91B revenue and $8.65-$9.00 non-GAAP EPS, and repurchased $332.8M of stock.

yahoo.com6 min